Compare · GLP-1 agonist
Ecnoglutide vs Mazdutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Mazdutide | |
|---|---|---|
| Evidence | 7/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it…
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that switches on two of the body's metabolic hormone receptors at the same time. Most of the buzzy GLP-1 compounds are still stuck at the press-release stage, but mazdutide is further along: it has a full Phase 3 trial published in…